T Kauttu1,2, H Mustonen2,3, S Vainionpää3, L Krogerus4, I Ilonen1,2, J Räsänen1,2, J Salo1,2, P Puolakkainen5,6. 1. Department of General Thoracic and Esophageal Surgery, Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland. 2. Department of Surgery, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland. 3. Department of Gastroenterologic and General Surgery, Helsinki University Hospital, Haartmaninkatu 4, PO Box 340, 00290, Helsinki, Finland. 4. Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland. 5. Department of Surgery, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland. pauli.puolakkainen@hus.fi. 6. Department of Gastroenterologic and General Surgery, Helsinki University Hospital, Haartmaninkatu 4, PO Box 340, 00290, Helsinki, Finland. pauli.puolakkainen@hus.fi.
Abstract
BACKGROUND: Clinically useful marker molecules for the progression of gastroesophageal reflux disease and Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) are lacking. Many adenocarcinomas and inflammatory conditions exhibit increased expression of ADAMs, 'a disintegrin and metalloproteinases'. METHODS: We assessed the expression of five ADAMs (9, 10, 12, 17, 19) in three esophageal cell lines (Het-1A, OE19, OE33) by RT-PCR and Western blotting, and in human samples of normal esophagus, esophagitis, BE, Barrett's dysplasia, and EAC by RT-PCR, and in selected samples by immunohistochemistry. RESULTS:EAC patients showed increased mRNA expression of ADAMs 9, 12, 17 and 19, as compared to controls. At immunohistochemistry, ADAM9 and ADAM10 proteins were increased in EAC. Patient samples also showed increased mRNA expression of ADAM12 in esophagitis, of ADAM9 in BE, and of ADAMs 9, 12 and 19 in Barrett's dysplasia, as compared to controls. Two EAC cell lines showed increased ADAM9 mRNA. CONCLUSIONS:ADAM9 expression is increased in EAC. Its predecessors show increased ADAM9 mRNA expression. The importance of the alterations in ADAM expression for the development of EAC, and their use as marker molecules, warrant further studies.
RCT Entities:
BACKGROUND: Clinically useful marker molecules for the progression of gastroesophageal reflux disease and Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) are lacking. Many adenocarcinomas and inflammatory conditions exhibit increased expression of ADAMs, 'a disintegrin and metalloproteinases'. METHODS: We assessed the expression of five ADAMs (9, 10, 12, 17, 19) in three esophageal cell lines (Het-1A, OE19, OE33) by RT-PCR and Western blotting, and in human samples of normal esophagus, esophagitis, BE, Barrett's dysplasia, and EAC by RT-PCR, and in selected samples by immunohistochemistry. RESULTS: EAC patients showed increased mRNA expression of ADAMs 9, 12, 17 and 19, as compared to controls. At immunohistochemistry, ADAM9 and ADAM10 proteins were increased in EAC. Patient samples also showed increased mRNA expression of ADAM12 in esophagitis, of ADAM9 in BE, and of ADAMs 9, 12 and 19 in Barrett's dysplasia, as compared to controls. Two EAC cell lines showed increased ADAM9 mRNA. CONCLUSIONS:ADAM9 expression is increased in EAC. Its predecessors show increased ADAM9 mRNA expression. The importance of the alterations in ADAM expression for the development of EAC, and their use as marker molecules, warrant further studies.
Entities:
Keywords:
ADAM molecules; Barrett’s esophagus; Esophageal adenocarcinoma; Gastroesophageal reflux disease
Authors: Tetsuro Yoshimura; Toshihiko Tomita; Michael F Dixon; Anthony T R Axon; Philip A Robinson; Jean E Crabtree Journal: J Infect Dis Date: 2002-01-17 Impact factor: 5.226
Authors: Irina Kerna; Kalle Kisand; Siim Suutre; Maret Murde; Ann Tamm; Jaanika Kumm; Agu Tamm Journal: Joint Bone Spine Date: 2013-04-09 Impact factor: 4.929
Authors: C Mongaret; J Alexandre; A Thomas-Schoemann; E Bermudez; C Chéreau; C Nicco; F Goldwasser; B Weill; F Batteux; F Lemare Journal: Int J Cancer Date: 2010-12-09 Impact factor: 7.396
Authors: Amel Saadi; Nicholas B Shannon; Pierre Lao-Sirieix; Maria O'Donovan; Elaine Walker; Nicholas J Clemons; James S Hardwick; Chunsheng Zhang; Madhumita Das; Vicki Save; Marco Novelli; Frances Balkwill; Rebecca C Fitzgerald Journal: Proc Natl Acad Sci U S A Date: 2010-01-13 Impact factor: 11.205
Authors: J P Baren; G D Stewart; A Stokes; K Gray; C J Pennington; R O'Neill; D A C Deans; S Paterson-Brown; A C P Riddick; D R Edwards; K C H Fearon; J A Ross; R J E Skipworth Journal: Br J Cancer Date: 2012-06-07 Impact factor: 7.640
Authors: R Grützmann; J Lüttges; B Sipos; O Ammerpohl; F Dobrowolski; I Alldinger; S Kersting; D Ockert; R Koch; H Kalthoff; H K Schackert; H D Saeger; G Klöppel; C Pilarsky Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640
Authors: Tong Jiao; Ye Yao; Bo Zhang; Da-Cheng Hao; Qing-Feng Sun; Jing-Bo Li; Chao Yuan; Bao Jing; Yun-Peng Wang; Hai-Yang Wang Journal: Biomed Res Int Date: 2017-03-05 Impact factor: 3.411